MedTrace Logo

Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)

NCT05481801 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-02-08

No results posted yet for this study

Summary

Observational study about adherence to guidelines for Covid-19, Influenza, Pneumococcal and Hepatitis B Vaccination in adult patients with type 1 Diabetes mellitus.

Conditions

Interventions

BIOLOGICAL

Covid-19 vaccination

Correct Covid19 vaccination status was considered in the following situation: Received at least two Covid-19 vaccine doses being the last in the last 6 months.

BIOLOGICAL

Influenza vaccination

Correct influenza vaccination status was considered in the following situation: \- Received at least one Influenza vaccine dose in the last year.

BIOLOGICAL

Pneumococal vaccination

Correct pneumococal vaccination status was considered if a subject received at least one of the following options: One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months. One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year.

BIOLOGICAL

Hepatitis B Virus (HBV) vaccination

Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation: .- Received at least three consecutive doses of HBV vaccine during six consecutive months.

Sponsors & Collaborators

  • Castilla-La Mancha Health Service

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2022-12-01
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481801 on ClinicalTrials.gov